Therapeutic resistance is a major challenge in metastatic prostate cancer, with over half of patients acquiring resistance within two years of starting treatment. Resistance can occur when cancer cells hijack a process called lineage plasticity, in which cells change identities during development or in response to stress, and ultimately escape treatment. In prostate cancer, cells turn down genes in the hormone androgen receptor (AR) pathway, which most treatments target, and turn on genes in the neuroendocrine (NE) pathway, allowing cells to differentiate into nerve and hormone-producing cells. Studies have partially explained how this happens, pointing to epigenetic and transcriptional reprogramming, which changes how AR genes are turned on and off. However, the role of mRNA translation in lineage plasticity remains an open question.
One key player in mRNA translation is the transfer RNA (tRNA) molecule. tRNAs canonically deliver the amino acids required to decode mRNA transcripts and produce polypeptide chains, which are further assembled into proteins. However, tRNAs are more than just amino acid suppliers. These molecules are extraordinarily diverse, with distinct combinations of anticodon sequences, body sequences, and chemical modifications, all of which determine their specificity and function. Specific tRNAs have been associated with proliferation in breast cancer and metastasis in melanoma. But many questions linger including: What are the tRNAs involved in lineage transition and therapeutic resistance in prostate cancer?
Researchers in the Hsieh lab at Fred Hutch Cancer Center pursued this question in a recent Nature publication by investigating the tRNA profile in prostate cancer. In a study led by post-doctoral fellow Dr. Yeon Soo Kim, prostate cancer cell lines were engineered to adopt two distinct states: conventional adenocarcinoma (AD) or differentiated lineage plastic (LP). The team performed multiplex small RNA sequencing and discovered that one tRNA, tRNA1Arg (UCU), showed the biggest difference between cell types: it was more abundant in AD cells and less abundant in LP cells. This specific tRNA carries the amino acid arginine and, through its UCU anticodon, recognizes the AGA codon in mRNA, to add arginine to the growing polypeptide chain. To test whether this pattern held in patients, the team analyzed tumor samples from 56 patients in the University of Washington prostate cancer rapid autopsy cohort. Excitingly, they observed that tRNA1Arg (UCU) levels were high in androgen receptor-driven tumors and low in neuroendocrine tumors, consistent with the lineage plastic phenotype.
To distinguish whether tRNA1Arg (UCU) is a marker or a driver of lineage plasticity, Kim and colleagues studied how prostate cancer responds to treatment following tRNA1Arg (UCU) knockdown. The team developed a cancer mouse model haplo-insufficient for n-Trtct2; in which the mouse only has one functional copy of the gene that encodes for tRNA1Arg (UCU). Mice underwent surgical castration to model androgen deprivation. They discovered that cells from haplo-insufficient mice were more resistant to androgen deprivation than those from mice with wildtype n-Trtct2, suggesting that low levels of tRNA1Arg (UCU) drives castration resistance in prostate cancer. Strikingly, overexpressing n-Trtct2 both reduced neoplasia pathology and reversed the castration-resistant phenotype in mice. Together, these findings underscore the novel functional relevance of tRNA1Arg (UCU) and tRNA dosage in sensitivity to AR-targeted therapy in prostate cancer.
With the goal of uncovering the other molecular players involved, the authors leveraged CHIP-seq data to identify 11 DNA-binding proteins that bind at the gene locus TRR-TCT1-1, the site of tRNA1Arg (UCU) transcription. Only the knockdown of two candidate genes TARDBP and ZSCAN29, decreased tRNA1Arg (UCU) levels, implicating both as key regulators. CUT&RUN experiments further confirmed that TARDBP and ZSCAN29 expression was only downregulated at this locus in LP cells, with reduced RNA polymerase III binding and transcriptional activity, suggesting that these proteins orchestrate tRNA1Arg (UCU) transcription.
The final piece of the puzzle was understanding the mechanism by which tRNA1Arg (UCU) drives lineage transition in prostate cancer. The authors identified SMARCC2, a member of the SWI/SNF protein complex, as a key downstream target of tRNA1Arg (UCU) translation. This complex modulates how tightly DNA is wrapped around histone proteins and thereby regulates expression of genes in the AR pathway. Kim and colleagues observed that SMARCC2 gene expression decreased during lineage transition and was restored upon the rescue of tRNA1Arg (UCU) at the translational level. This result suggests that tRNA1Arg (UCU) controls the expression of SMARCC2, which may rewire the epigenetic landscape to facilitate AR activity; directly linking tRNA-mediated translation to downstream epigenetic changes.
Principal investigator Dr. Andrew Hsieh remarked “This work shows for the first time that tRNAs can alter the identity and drug sensitivity of cancer. This represents a new framework for considering the process of lineage plasticity and has implications for how we study the shape shifting nature of this disease.” This landmark study only marks the beginning of unravelling the role of tRNAs in lineage plasticity. Hsieh raises potential future directions such as “Can we therapeutically engineer this tRNA to prevent lineage plasticity? Is tRNA1Arg (UCU) unique to prostate cancer?” As tRNA biology continues to emerge as a regulatory force in cancer, these findings suggest that targeting tRNA abundance may offer a promising new therapeutic avenue for overcoming resistance in metastatic prostate cancer.
UW/Fred Hutch Cancer Consortium members Andrew Hsieh, Arvind Subramaniam, Colm Morrissey, Eva Corey, Michael Haffner, Gavin Ha, and Peter Nelson contributed to this work.
The spotlighted research was supported by the National Institutes of Health, Prostate Cancer Foundation Challenge Award, Seattle Translational Tumor Research, the American Cancer Society, and philanthropic donations.
Kim YS, Arora S, Young D, Tsou A, Shiuan A, Wladyka CL, Rudoy D, Kim JY, Waters JA, Schuster SL, Coleman IM, Kapur M, Sobczyk M, Katanski CD, Bayat Tork AM, Zhang W, Nelson PS, Ha G, Haffner MC, Corey E, Morrissey C, Wang Y, Subramaniam AR, Lee JK, Ackerman SL, Pan T, Hsieh AC. 2026. tRNA dosage regulates lineage dependency and resistance in prostate cancer. Nature. DOI: 10.1038/s41586-026-11153-8